OncoZenge AB (publ) (FRA:8LY)

Market Cap	6.23M +22.5%
Revenue (ttm)	251.72K +69,475.0%
Net Income	-773.81K
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.4640
Previous Close	0.4905
Day's Range	0.4640 - 0.4640
52-Week Range	0.3400 - 0.6680
Beta	n/a
RSI	45.58
Earnings Date	Feb 18, 2026

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 1
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8LY

Financial Performance

In 2024, OncoZenge AB's revenue was 1,000, a decrease of -66.67% compared to the previous year's 3,000. Losses were -8.69 million, -45.37% less than in 2023.

Financial numbers in SEK